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scored highest as reasons for not taking medications as pre-
scribed. The median PDC for antihypertensive drugs was 57%,
less than 40% had PDC >80%, with newly treated hypertensive
patients commonly =<80% PDC. 35% would be less likely or
much less likely to miss a dose if two pills would be combined
in one tablet, this likelihood was independent of CVD, experi-
enced or new use and calculated PDC levels. Perceived likeliness
to beneﬁt from a combined tablet was signiﬁcantly higher in
persons taking fewer AH drugs, and patients self-reporting
taking =<20% of doses. CONCLUSION: Patients newly treated
with antihypertensive drugs and additional cardiovascular risk
factors may beneﬁt most from a ﬁxed combination of two car-
diovascular risk reducing drugs in one pill since they express
more partial adherence and use fewer tablets.
PCV87
COMPARING COMPLIANCE AND PERSISTENCE RATES FOR
HYPERTENSION, DYSLIPIDEMIA,AND DIABETES
MEDICATIONS
Cramer JA1, Benedict A2, Muszbek N3, Keskinaslan A4, Khan ZM5
1Yale University School of Medicine, West Haven, CT, USA,
2UnitedBiosource Corporation, Budapest, Hungary, 3UnitedBiosource
Corporation, London, UK, 4Novartis Pharma AG, Basel, Switzerland,
5Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: Noncompliance and non-persistence with long-
term medication is a serious world-wide problem that leads to
compromised health beneﬁts and serious economic conse-
quences. A systematic literature review was conducted to
compare rates of compliance and persistence among studies 
of treatments for hypertension, dyslipidemia, and diabetes.
METHODS: A search of the literature (2000–2005) was focused
on publications that provided a numeric measure of medication
compliance and/or persistence, an adequate description of
methods, and numeric compliance and/or persistence rates for
antihypertensives (AHT), lipid-lowering therapy (LLT), or oral
antidiabetics (OAD). Studies were classiﬁed according to their
source of data into pharmacy claims and electronic monitors
(Medication Event Monitoring System, MEMS), and by study
design into retrospective and prospective studies. Results
reported as medication possession ratio (MPR) were extracted
and averaged over the treatment arms of the studies. Compliance
rates were compared across study design and treatment class.
RESULTS: The literature review resulted in 139 studies assess-
ing treatment with one or more targeted medications: AHT =53,
LLT =32, OAD =35, multiple treatments =19. Twelve-month
compliance rates averaged 67% for AHT, 74% for LLT, and
76% for OAD drugs (overall 72 ± 18%).Compliance rates aver-
aged 79% among prospective and 71% among retrospective
studies (NS). Persistence estimates at 12 months from 22 studies
ranged between 35% and 92% (mean 63 ± 18%). Thirty-ﬁve
percent of the reports related compliance to treatment outcomes.
Similar proportions were observed across classes. The propor-
tion of MEMS studies reporting outcomes related to compliance
or persistence was higher than studies based on pharmacy claims:
clinical consequences (52% vs. 18%), health care utilization
(14% vs 4%), and lower for no outcome data (33% vs. 78%)
(p = 0.004). CONCLUSION: These data indicated comparable
compliance and persistence rates across treatments for hyper-
tension, dyslipidemia, and diabetes with three-fourths of med-
ication taken as prescribed and two-thirds of patients continuing
for one year.
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OBJECTIVES: Assess prevalence and discontinuation rates 
of antidyslipidemic therapy in patients with dyslipidemia.
METHODS: We conducted a retrospective cohort study using a
large US national database of electronic medical records con-
taining diagnosis, lab and medication information. Users of 
antidyslipidemics were identiﬁed. Prevalence of six classes of
antidyslipidemics was described and one-year discontinuation
rate was calculated. Logistic regression model was used to eval-
uate factors affecting drug discontinuation. RESULTS: We iden-
tiﬁed 153,505 patients who started antidyslipidemic therapy
from 1997 to 2004 and were followed for one year after drug
initiation. Among 214,440 distinct treatment regimen initiations,
79.5% were statins, with atorvastatin (52.7%) and simvastatin
(24.0%) being the most frequently prescribed. Prevalence of
other classes of antidyslipidemics was: 8.8% for ﬁbrates, 5.3%
for cholesterol absorption inhibitors, 3.3% for niacin, 2.7% for
bile acid-binding resins, and 0.5% for combination formula-
tions. One-year discontinuation rate was 28.6% for statins,
31.8% for cholesterol absorption inhibitors, 34.1% for ﬁbrates,
40.7% for combination formulations, 44.7% for niacin, and
50.1% for bile acid-biding resins. Logistic regression showed
that statin users were less likely to stop therapy than patients on
other classes (odds ratio (OR): 0.63). Surprisingly, patients with
coronary hear disease (OR: 1.22) and diabetes (OR: 1.13) were
more likely to discontinue treatment than patients without those
conditions; high LDL-C or TG and low HDL-C were also found
to be associated with higher rates of medication discontinuation
at one year. CONCLUSIONS: Our study showed that signiﬁcant
variation exists in medication discontinuation among different
classes of antidyslipidemics. Medications targeting to raise HDL-
C or lower TG had higher discontinuation rate, implying that
there were unmet needs for the treatment of abnormal HDL-C
or TG. High discontinuation rate for patients at high risk for
cardiovascular disease was a major concern. Further studies are
needed to assess the consequences and implications of medica-
tion discontinuation.
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OBJECTIVE: To evaluate the impact of patient beliefs on med-
ication non-adherence for the purpose of crafting medication
adherence messages for disease management programs.
METHODS: In late 2005, 5630 respondents to the Thomson
Medstat PULSE health behavior survey, a nationally representa-
tive U.S. survey, reported having high cholesterol. Respondents
received additional cholesterol-speciﬁc questions beyond demo-
graphic/clinical questions already part of the survey. Beliefs
about the necessity of and concerns about taking their medica-
tions were assessed via ﬁve likert-scale questions each with
summed scores ranging between ﬁve and 25. A cut-point of 15
was used to identify high versus low necessity or concerns. Four
patient segments resulted representing high necessity/high
concern, low necessity/high concern, low necessity/low concern,
